NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 Russian patent published in 2024 - IPC C07K14/47 C07K16/28 C07K19/00 C12P21/02 A61K38/17 A61K39/395 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to fusion proteins specific to both cluster of differentiation 137 (CD137), and to ligand of programmed cell death 1 (PD-L1), and can be used in medicine for treating PD-L1-positive cancer. Disclosed is a fused protein having two or three subunits linked by a linker, wherein the first subunit comprises a full-length immunoglobulin that specifically binds PD-L1, the second subunit or the second subunit and the third subunit both contain a lipocalin mutein which specifically binds CD137. Second subunit can be linked to the end of each heavy chain of the first subunit or to the end of each light chain of the first subunit, and the third subunit is with the C-end of each second subunit or with the C-end of each light chain of the first subunit.

EFFECT: invention enables to obtain fusion proteins effective in costimulation of lymphocyte activation in a PD-L1 target-dependent manner.

23 cl, 19 dwg, 13 tbl, 22 ex